Your medical implant or food wrapper could someday be made of CBD

Cannabis (Cannabis sativa) is well known for the euphoric "high" it gives users, caused by a chemical called tetrahydrocannabinol (THC). Another component, CBD, is responsible for feelings of relaxation and calmness, but unlike THC, it doesn't produce a high. In hemp plants bred to contain little-to-no THC, CBD can make up to 20% of the plant's weight. Because it's now federally legal in the U.S. to grow hemp, the price of CBD has dropped dramatically, opening up the possibility of using CBD in other applications.

In recent years, the bioplastic called poly(lactic acid), or PLA, has become a popular option for sustainable plastics because it's made from corn and sugarcane instead of fossil fuels, and can be industrially composted. Many single-use consumer goods, such as utensils and soda bottles, as well as medical devices, such as facial fillers and implants, now contain PLA. Just as lactic acid is a good building block for PLA, CBD's chemical structure also has the right stuff to be repeated as a polymer. So, Gregory Sotzing, Lakshmi Nair and colleagues wanted to see whether CBD could be used to make a new bioplastic.

To create cannabinoid polymers, the researchers performed a condensation reaction with adipoyl chloride -- also used to create nylon -- and either CBD or the closely-related cannabigerol (CBG), producing a polyester. Polymeric CBD had a broad melting temperature range and stretchability, and to show its ability to function as a plastic, the researchers formed it into a hemp leaf shape with a mold. Because bioplastics are often used in medical contexts, they also investigated the polymers' bioactive properties. Neither CBD nor CBG polyesters was cytotoxic. Unlike the conventional bioplastic PLA, the CBD polyester had an antioxidant activity. Although the polymer version of CBD didn't confer the same therapeutic effects as it does in oil form, Sotzing says that future versions of the plastic could be engineered to have anti-inflammatory and pain-relieving properties, and this is the goal of his start-up company Polycannabinoid Therapeutics Rx.

The authors acknowledge funding from the National Institutes of Health for the biological aspects of this work.